WASHINGTON UNIVERSITY SCHOOL OF MEDICINE

InspireMD secures FDA approval for CGUARDIANS II study of CGuard Prime 80cm carotid stent system during TCAR procedures, with Patrick Geraghty and Patrick Muck as lead investigators. The study aims to optimize CGuard Prime for TCAR and advance the SwitchGuard NPS system for stroke prevention and carotid disease management.

The FDA approved a self-administered nasal flu vaccine, FluMist, for adults 18-49 and children 2-17 with caregiver assistance, available online. This follows the CDC's recommendation for nasal flu sprays in children. Researchers anticipate more vaccines in nasal form, including for Alzheimer's and heart rhythms, due to superior airway immunity.

Setrusumab (UX143) received FDA Breakthrough Therapy Designation for reducing fracture risk in osteogenesis imperfecta (OI) type 1, 3, or 4 patients aged 2 and older. The treatment, a fully human monoclonal antibody, targets sclerostin to enhance bone formation and density. Positive phase 2 ORBIT study results showed a 67% reduction in fractures and ongoing improvements in bone mineral density.

InspireMD receives FDA IDE for CGuard Prime 80cm carotid stent system, enabling CGUARDIANS II pivotal study for transcarid revascularization (TCAR) procedures, with Dr. Patrick Geraghty and Dr. Patrick Muck as lead investigators.

InspireMD, Inc. announced FDA approval of its IDE Application for the CGUARDIANS II pivotal study of the CGuard Prime 80cm Carotid Stent System during TCAR procedures, with Drs. Patrick Geraghty and Patrick Muck as lead investigators. The study aims to optimize CGuard Prime for TCAR and advance the SwitchGuard NPS for future commercial sales in the U.S.

InspireMD, Inc. announced FDA approval for its CGUARDIANS II pivotal study of CGuard Prime 80cm Carotid Stent System during TCAR procedures, with Drs. Patrick Geraghty and Patrick Muck as lead investigators. The study aims to optimize CGuard Prime for TCAR and advance the SwitchGuard NPS for future commercial sales in the U.S.

WashU Medicine study finds accelerated aging in younger people linked to higher risk of early-onset cancers, suggesting potential need for earlier screenings.

Theriva Biologics announces positive DSMC review of SYN-004 trial results in allogeneic HCT recipients, with no AEs related to study drug. DSMC recommends proceeding to Cohort 3 with SYN-004 combined with cefepime.

Brazilian researchers propose targeting glutaminase and HuR for breast cancer treatment, as both are crucial for tumor progression. Glutaminase converts glutamine to glutamate, fueling cancer cell growth, while HuR regulates its RNA metabolism. Inhibiting both could significantly reduce breast cancer cell growth and invasion.